UT-MD Anderson Cancer Center: Combining Immunotherapy With KRAS Inhibitor Eliminates Advanced KRAS-Mutant Pancreatic Cancer in Preclinical Models
August 25, 2023
August 25, 2023
HOUSTON, Texas, Aug. 25 (TNSres) -- The University of Texas's MD Anderson Cancer Center issued the following news release:
* * *
Comprehensive MD Anderson studies accelerate new discovery into pharmacological application and Phase I trial
* * *
Researchers at The University of Texas MD Anderson Cancer Center have uncovered a functional role for KRAS mutations in pancreatic cancer and rapidly translated these findings into a novel therapeutic ap . . .
* * *
Comprehensive MD Anderson studies accelerate new discovery into pharmacological application and Phase I trial
* * *
Researchers at The University of Texas MD Anderson Cancer Center have uncovered a functional role for KRAS mutations in pancreatic cancer and rapidly translated these findings into a novel therapeutic ap . . .